Cost per milligram: difference between revisions
Diff·revision 16 → 17·12:43, 19 Jul 2025
Difference between revision 16 and revision 17 of Cost per milligram. 7 lines changed; the page grew by 735 bytes.
| Revision 16 — 23:03, 4 Jul 2025 TSH_Tallulah (talk) expand §Approved products 3,292 bytes ±0 | Revision 17 — 12:43, 19 Jul 2025 CategoryBot (talk) bot: add stub category 4,027 bytes +735 | ||
|---|---|---|---|
| 33 | Comparing a price against a thinner document set is comparing two different things, which is a factual observation rather than an argument for paying more.{{r|usp1503}} | 33 | Comparing a price against a thinner document set is comparing two different things, which is a factual observation rather than an argument for paying more.{{r|usp1503}} |
| 34 | 34 | ||
| + | 35 | == Approved products == | |
| + | 36 | For licensed medicines, price comparison involves list price, net price after rebate, formulary position and patient contribution, which are different numbers serving different purposes. A list price is rarely what anyone pays.{{r|ada2024}} | |
| + | 37 | ||
| + | 38 | Cost per milligram is not usually the relevant unit there either, since dosing is by product-specific dose steps rather than by mass alone. Cost per month at a given dose is the comparison clinicians and payers use. See [[Prior authorisation]] and [[Insurance coverage of GLP-1 drugs]].{{r|ada2024}} | |
| + | 39 | ||
| 35 | == References == | 40 | == References == |
| 36 | {{reflist}} | 41 | {{reflist}} |
| 37 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 42 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 38 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | 43 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> |
| + | 44 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | |
| 39 | <ref name="ich_q7">International Council for Harmonisation, ''Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients'' (2000).</ref> | 45 | <ref name="ich_q7">International Council for Harmonisation, ''Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients'' (2000).</ref> |
| 40 | 46 | ||
| ⋮ | ⋮ | ||
| 44 | * [[Trifluoroacetate counterion]] | 50 | * [[Trifluoroacetate counterion]] |
| 45 | * [[Certificate of analysis]] | 51 | * [[Certificate of analysis]] |
| + | 52 | * [[Insurance coverage of GLP-1 drugs]] | |
| 46 | 53 | ||
| 47 | {{DEFAULTSORT:Cost per milligram}} | 54 | {{DEFAULTSORT:Cost per milligram}} |